Company Analysis

NRX Pharmaceuticals, Inc. (NRXP)

Nasdaq: NRXP · Pharmaceutical Preparations · Wilmington, DE · filing with the SEC since 2017
Grade2.8
◀ Past 3.7● Present 1.7▶ Future 3.2
3 est.

Who runs NRX Pharmaceuticals, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Javitt Jonathan C
CEO and Chairman. First filing May 2021, latest Nov 4, 2026, 6 filings in all.
Officers reporting now
3
of 6 people with a filing in the last fifteen months
Directors reporting now
3
27 people on the record since 2017
Officerssales are open-market, Nov 4, 2025 to Nov 4, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Javitt Jonathan CCEO and ChairmanMay 2021Nov 4, 2026none
Abrams Michael SChief Financial OfficerNov 2024Nov 4, 2026none
Casper Joseph MichaelChief Operating OfficerFeb 2026Feb 17, 2026none
Directorssales are open-market, Nov 4, 2025 to Nov 4, 2026
NameRoleFirst filingLatest filingSales, 12 months
Flynn Patrick JohndirectorMay 2021Sep 10, 2025none
Hurvitz ChaimdirectorMay 2021Sep 10, 2025none
Mcbride DennisdirectorJun 2024Sep 10, 2025none
Owners of more than 10% of a classsales are open-market, Nov 4, 2025 to Nov 4, 2026
NameRoleFirst filingLatest filingSales, 12 months
B Group, Inc.10% ownerAug 2025Aug 21, 2025none
Earlier names on the record26, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton NRXP · research, not advice